RTTNews | Dec 17, 2021 10:09AM EST

10:09 Friday, December 17, 2021 (RTTNews.com) - Bellerophon Therapeutics, Inc. (BLPH) shares are surging more than 34 percent on Friday morning trade after the clinical-stage company reported positive top-line data from Phase 2 acute dose-escalation study of INOpulse for pulmonary hypertension associated with Sarcoidosis. Based on the reduction in pulmonary vascular resistance in the proof-of-concept study, Bellerophon plans to design multi-dose Phase 2b trial.

Currently, shares are at $3.18, up 34.96 percent from the previous close of $2.37 on a volume of 22,875,658. For the 52-week period, the shares have traded in a range of $2.34-$9.18 on average volume of 41,880.

Read the original article on RTTNews ( https://www.rttnews.com/3250291/what-is-pushing-bellerophon-stock.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved